Spots Global Cancer Trial Database for Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer
Official Title: A Phase II, Single-arm, Two-cohorts, Open-label, Single Center Study of Surufatinib or Surufatinib Combined With Vinorelbine as Third-line and Posterior Line Treatment in Patients With Non-Small Cell Lung Cancer
Study ID: NCT04922658
Conditions
Study Description
Brief Summary: A phase II study to assess the efficacy and safety of Surufatinib or Surufatinib combined with Vinorelbine as third-line and posterior line treatment in patients with NSCLC
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, Guangdong, China
Contact Details
Name: Yanfang Zheng, M.D., Ph.D.
Affiliation: Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
